- Home
- ALGS vs YI Comparison
ALGS vs YI Comparison
Compare ALGS & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- YI
- Stock Information
- Founded
- ALGS 2018
- YI 2010
- Country
- ALGS United States
- YI China
- Employees
- ALGS N/A
- YI N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- YI Retail-Drug Stores and Proprietary Stores
- Sector
- ALGS Health Care
- YI Consumer Staples
- Exchange
- ALGS Nasdaq
- YI Nasdaq
- Market Cap
- ALGS 53.0M
- YI 60.7M
- IPO Year
- ALGS 2020
- YI N/A
- Fundamental
- Price
- ALGS $9.99
- YI $5.42
- Analyst Decision
- ALGS Strong Buy
- YI
- Analyst Count
- ALGS 2
- YI 0
- Target Price
- ALGS $60.00
- YI N/A
- AVG Volume (30 Days)
- ALGS 71.7K
- YI 22.3K
- Earning Date
- ALGS 11-05-2025
- YI 09-17-2025
- Dividend Yield
- ALGS N/A
- YI N/A
- EPS Growth
- ALGS N/A
- YI N/A
- EPS
- ALGS N/A
- YI N/A
- Revenue
- ALGS $3,174,000.00
- YI $1,979,883,442.00
- Revenue This Year
- ALGS N/A
- YI N/A
- Revenue Next Year
- ALGS $28.79
- YI N/A
- P/E Ratio
- ALGS N/A
- YI N/A
- Revenue Growth
- ALGS N/A
- YI N/A
- 52 Week Low
- ALGS $3.76
- YI $4.15
- 52 Week High
- ALGS $46.80
- YI $11.90
- Technical
- Relative Strength Index (RSI)
- ALGS 51.70
- YI 32.37
- Support Level
- ALGS $8.90
- YI $5.51
- Resistance Level
- ALGS $11.65
- YI $6.37
- Average True Range (ATR)
- ALGS 0.76
- YI 0.54
- MACD
- ALGS -0.25
- YI -0.03
- Stochastic Oscillator
- ALGS 39.64
- YI 4.42
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.